Search Results

Search Results

Research Study Search Results

Return to Search Form
  1. Cancer (Oncology)

    1. Psychoeducation for Spouses of Women with Breast Cancer Frances M. Lewis, PhD, RN, FAAN (University of Washington)
    1. Breast

      1. SWOG 1207: Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer – e3 Breast Cancer Study Gary Goodman, M.D.
      2. SWOG 1202: A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer Gary Goodman, M.D.
      3. SWOG 1007: A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less Gary Goodman, M.D.
      4. NSABP B-50-I (Katherine): Trastuzumab Emtansine versus Trastuzumab as Adjuvant Therapy for Patients with HER2+ Primary Breast Cancer Who have Residual Tumor Present Pathologically in the Breast or Axillary lymph Nodes Following Preoperative Therapy Tanya Wahl, M.D.
      5. E2112 :A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer Gary Goodman, M.D.
      6. CTSU E2108: A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Christine Lee, M.D.
      7. CTSU B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of TC or Four Cycles of AC Followed by Four Cycles of Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-N Gary Goodman, M.D.
      8. CTSU B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy Gary Goodman, M.D.
      9. CRC 14034: A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer Erin Ellis, M.D.
      10. CRC 13105: A Randomized Phase 2 Study of Veliparib plus Temozolomide or Veliparib plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects with BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer Erin Ellis, M.D.
      11. CRC 11105: Prevention of Recurrence in Early-Stage,Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax(TM) Treatment Kristine Rinn, M.D. and Henry Kaplan, M.D.
      12. CRC 10016: I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2) Erin Ellis, M.D. and Henry Kaplan, M.D.
    2. Cancer Detection Program

      1. Ovarian Cancer Early Detection Program Pamela Paley, M.D.
      2. Flight Attendants Medical Research Institute (FAMRI) – International Early Lung Cancer Action Program (IELCAP) Protocol Ralph Aye, M.D.
    3. Colon

      1. SWOG 0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon Cancer, Phase III Gary Goodman, M.D.
      2. CTSU C80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer Gary Goodman, M.D.
    4. Colorectal

      1. SWOG 1008: Feasibility Study of a Physical Activity and Dietary Change Weight Loss Intervention In Breast and Colorectal Cancer Survivors, Phase II Gary Goodman, M.D.
      2. CRC 10097: Phase Ib with Expansion of Patients at the MTD Study of AUY922 and Cetuximab in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Philip Gold, M.D.
    5. Endometrial

      1. Investigating the Use of Fluorescence Imaging in Endometrial Cancer Surgery Pamela Paley, M.D.
    6. Esophageal

      1. SWOG 1201: A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastroesophageal Junction (GEJ) Cancer Gary Goodman, M.D.
      2. CTSU R1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment Of HER2-Overexpressing Esophageal Adenocarcinoma Gary Goodman, M.D.
    7. Gallbladder or Bile Duct

      1. Gastroesophageal Junction

        1. SWOG 1201: A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastroesophageal Junction (GEJ) Cancer Gary Goodman, M.D.
      2. Kidney

        1. SWOG 1107: Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination With Erlotinib in Papillary Renal Cell Carcinoma Gary Goodman, M.D.
        2. SWOG 0931: EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study Gary Goodman, M.D.
      3. Leukemia

        1. SWOG 0919: A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Poor-Risk Acute Myelogenous Leukemia (AML) Gary Goodman, M.D.
        2. CRC 13084: Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission Michael Milder, M.D.
        3. CRC 11060: Studying Interventions for Managing Patients with Chronic Myeloid Leukemia in Chronic Phase I: The 5-Year Prospective Cohort Study (SIMPLICITY) Kenneth Kraemer, M.D.
      4. Liver

        1. CTSU E1208: A Phase III Randomized, Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion Gary Goodman, M.D.
        2. CTSU C80802: Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Gary Goodman, M.D.
        3. CRC 13091: A Phase III, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib Philip Gold, M.D.
      5. Lung

        1. SWOG 1206: A Dose Finding Study Followed by Phase II Randomized Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Gary Goodman, M.D.
        2. SWOG 0905: Randomized Phase II Study of Cediranib (NSC #732208) Versus Placebo in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Malignant Pleural Mesothelioma Gary Goodman, M.D.
        3. SWOG 0819: Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Gary Goodman, M.D.
        4. CTSU E5508: Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC Gary Goodman, M.D.
        5. CTSU C140503: A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (<=2 cm) Peripheral Non-Small Cell Lung Cancer Gary Goodman, M.D.
        6. CRC 14072: A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) Howard (Jack) West, M.D.
        7. CRC 14050: An Open Registry to Measure the Impact of Adding RNA Expression Testing on Referral Decisions in Newly Diagnosed Early Stage Lung Adenocarcinoma Patients Eric Vallieres, M.D.
        8. CRC 14035: An Open-label, Phase 1 Dose Escalation Study of Oral ASP8273 in Subjects with Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations Howard (Jack) West, M.D.
        9. CRC 14016: A Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer Stage IIIB, Stage IV or recurrent Howard (Jack) West, M.D.
        10. CRC 14015: Phase 3 Randomized, Placebo-Controlled, Double-blind, Multi-Center, Two-Part Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) Howard (Jack) West, M.D.
        11. CRC 14014: A Phase 3, Multicenter, Randomized, Open‐Label Cross-Over Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane) as Maintenance Treatment After Induction With Nab-Paclitaxel Plus Carboplatin in Subjects With Squamous Cell NSCLC Howard (Jack) West, M.D.
        12. CRC 14012: Phase II Study of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients with EGFR Mutation Who Have Previously Progressed on an EGFR-TKI Howard (Jack) West, M.D.
        13. CRC 13107: Double-Blind, Randomized, Placebo-Controlled Study of Selumetinib in Combination with Docetaxel, in Patients receiving second line treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (SELECT-1) Howard (Jack) West, M.D.
        14. CRC 13086: A Study of Heat Shock Protein 90 (HSP90) Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-Small Cell Lung Cancer (NSCLC) Howard (Jack) West, M.D.
        15. CRC 13049: Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib Howard (Jack) West, M.D.
        16. CRC 12104: A Phase I/II Study of the ALK Inhibitor CH5424802 in Patients with ALK-Rearranged Non-Small Cell Lung Cancer Howard (Jack) West, M.D.
        17. CRC 12058: A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors Howard (Jack) West, M.D.
        18. CRC 12046: A Randomized Study of Palifosfamide-tris in Combination with Carboplatin and Etoposide (PaCE) Chemotherapy vs Carboplatin and Etoposide (CE) Alone in Chemotherapy Naive Patients with Extensive-Stage Small Cell Lung Cancer Howard (Jack) West, M.D.
        19. CRC 09023: Collaborative Study on Sputum Cytology of Lung-Cancer Patients by the Swedish Cancer Institute and VisionGate, Inc Ralph Aye, M.D.
        20. A Phase II Multi-Center Study of the Tolerability of Weekly Nab-Paclitaxel as Second Line Treatment for Elderly Patients with Advanced Lung Cancer Howard (Jack) West, M.D.
      6. Lymphoma

        1. CTSU 9177: Phase II Study of Dose-Adjusted EPOCH+/- Rituximab in Adults With Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma Gary Goodman, M.D.
        2. CRC 13050: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Michael Milder, M.D.
      7. Multiple Myeloma

        1. CRC 13160: A Placebo-Controlled Study of Oral L-glutamine and Pyridoxal-5-phosphate (Vitamin B6) for the mitigation of Velcade-Induced Peripheral Neuropathy: A Pilot Study Michael Milder, M.D.
        2. CRC 13092: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma Henry Kaplan, M.D.
        3. CRC 13051: Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Michael Milder, M.D.
      8. Myelodysplastic Syndrome (MDS)

        1. CRC 13093: A Phase II Randomized, Double-Blinded, Placebo-Controlled Study of Pracinostat plus Azacitidine in Patients with Previously Untreated International Prognostic Scoring System (IPSS) Intermediate Risk 2 or High-Risk Myelodysplastic Syndrome (MDS) Michael Milder, M.D.
      9. Myeloproliferative Disorders

        1. CRC 11122: A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms Michael Milder, M.D.
      10. Ovarian

        1. CRC 11114: Phase Ib with Expansion of Patients at the MTD Study of Olaparib plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients Min Park, M.D.
      11. Peritoneal

        1. CRC 11006: Phase I Trial of Intraperitoneal nab-Paclitaxel (Abraxane®) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity Min Park, M.D.
      12. Prostate

        1. SWOG 1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer Gary Goodman, M.D.
        2. CTSU A031201: Phase III Trial of Enzalutamide versus Enzalutamide Abiraterone and Prednisone For Castration-Resistant Metastatic Prostate Cancer Gary Goodman, MD
        3. CRC 12061: A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer Howard (Jack) West, M.D.
      13. Rectal

        1. CTSU N1048: Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision Gary Goodman, M.D.
      14. Renal

        1. CTSU C90601: A Randomized Doubled-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma Gary Goodman, M.D.
      15. Solid Tumor or Hematologic Malignancy

        1. CRC 11055: A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy Henry Kaplan, M.D.
      16. Stomach

        1. SWOG 1201: A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastroesophageal Junction (GEJ) Cancer Gary Goodman, M.D.